Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07029217RecruitingPhase 3
Lower radiation dose study for B-cell lymphomas
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
Commack, New YorkAges 18 years+ - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Rockville Centre, New YorkAges 18–70 - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Rockville Centre, New YorkAges 18 years+ - NCT07010692RecruitingPhase 1/Phase 2
Treating skin cancers with laser and ointment
This trial tests a combination of fractional laser and tirbanibulin ointment to treat basal or squamous cell skin cancer that hasn't been treated before. It may offer a less invasive option for people with these common skin cancers.
New York, New YorkAges 18 years+ - NCT06995677RecruitingPhase 2
Study of TYRA-300 for bladder cancer that has not spread into muscle
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
Astoria, New YorkAges 18 years+ - NCT07002034RecruitingPhase 2
RE104 for adjustment disorder related to cancer or other serious illnesses
This trial is testing a new medication (RE104) for people who have adjustment disorder with depressed mood or anxiety because of a serious medical condition like cancer, ALS, MS, Parkinson's, or lung fibrosis. It's a study to see if the drug is safe and reduces symptoms.
Buffalo, New YorkAges 18–80 - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
New York, New YorkAges 18 years+ - NCT07001384RecruitingPhase 1
Alectinib and Duvelisib for ALK-positive anaplastic large cell lymphoma
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
New York, New YorkAges 18 years+ - NCT06989437RecruitingPhase 2/Phase 3
Study of Ponsegromab for Pancreatic Cancer with Weight Loss
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
New York, New YorkAges 18 years+ - NCT06992427RecruitingPhase 3
Gabapentin to prevent opioid use for mouth pain during cancer treatment
This trial tests if taking gabapentin during chemoradiation for head and neck cancer can reduce the need for strong painkillers like opioids. It may help manage mouth pain caused by treatment.
Buffalo, New YorkAges 18 years+ - NCT06991101RecruitingPhase 2
Ruxolitinib with radiation and chemo for newly diagnosed glioblastoma
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
New York, New YorkAges 18 years+ - NCT05241249RecruitingPhase 2
Bethanechol plus chemotherapy for pancreatic cancer
This trial tests whether adding bethanechol to standard chemotherapy (gemcitabine and nab-paclitaxel) can work better for people with pancreatic ductal adenocarcinoma. You may be considered if your cancer is not spread and you can safely take the medicines and follow study visits.
New York, New YorkAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
Lake Success, New YorkAges 18 years+ - NCT06977503Recruiting
Electrical stimulation with life coaching for burnout in healthcare workers
This study tests whether a gentle electrical headband used at home, plus online life coaching, can help reduce burnout symptoms in healthcare workers. You would attend three in-person visits and join group coaching sessions over about 15 weeks.
Buffalo, New YorkAges 21–75 - NCT06976476RecruitingPhase 2
IgPro20 to prevent infections in multiple myeloma patients on bispecific therapy
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
Commack, New YorkAges 18 years+ - NCT06960707RecruitingPhase 3
One vs two weeks of breast radiation after lumpectomy
This trial compares a shorter, one-week course of radiation to the standard two-week course after a lumpectomy for early-stage breast cancer. The goal is to see if one week is just as effective and safe, making treatment more convenient.
New York, New YorkAges Any age - NCT06934889RecruitingPhase 1
Study of investigational drugs with ERAS-801 for glioblastoma
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
Rockville Centre, New YorkAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
The Bronx, New YorkAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
New York, New YorkAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Buffalo, New YorkAges 18–59 - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Syracuse, New YorkAges 18 years+ - NCT06905197RecruitingPhase 1
Study of DZD6008 for advanced NSCLC with EGFR mutations
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
New York, New YorkAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
New York, New YorkAges 18 years+ - NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
New York, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Memorial Sloan Kettering Westchester · 6 studies
- Memorial Sloan Kettering Commack · 3 studies
- NYU Langone Health · 3 studies
- Roswell Park Comprehensive Cancer Center · 3 studies
- Associated Medical Professionals of NY · 2 studies
- Columbia University Irving Medical Center · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.